Samyang Group appoints former ST Pharm CEO as president of biopharma unit

Samyang Group said it has appointed Kim Kyung-jin, former CEO of ST Pharm, as the president of its biopharma unit. The company announced the decision on Monday as part of its annual personnel reshuffle and organizational restructuring.

The appointment marks the first round of changes following the group celebrating its 100th anniversary in October, where it announced plans to strengthen its core businesses with a focus on global and specialty markets, emphasizing high-value-added sectors.

Kim, the newly appointed president of the biopharma unit, brings extensive experience in both research and leadership roles.

After serving as a senior researcher at Roche, Kim held key positions at ST Pharm, including Head of Synthetic Research Division 1, Director of Research, and CEO.

Under Kim's leadership, Samyang’s Biopharma unit expects to intensify its global market expansion and enhance its contract development and manufacturing (CDMO) capabilities. The unit also plans to accelerate research and development efforts in messenger RNA (mRNA) delivery technologies.